首页ADAP • NASDAQ
add
Adaptimmune Therapeutics PLC - ADR
市场资讯
财务信息
损益表
收入
净收入
| (USD) | 2024年9月info | 年同比变化 |
|---|---|---|
收入 | 4090.10万 | 458.83% |
经营支出 | 2127.70万 | 31.63% |
净收入 | -1761.70万 | 61.37% |
净利润率 | -43.07 | 93.09% |
每股收益 | -0.01 | 70.15% |
息税折旧摊销前利润 | -1186.20万 | 72.88% |
有效税率 | -4.95% | — |
资产负债表
总资产
负债总额
| (USD) | 2024年9月info | 年同比变化 |
|---|---|---|
现金及短期投资 | 1.86亿 | 15.06% |
总资产 | 3.17亿 | 7.01% |
负债总额 | 2.37亿 | 13.88% |
权益总额 | 7998.90万 | — |
发行在外的股份 | 2.56亿 | — |
市净率 | 2.00 | — |
资产回报率 | -11.48% | — |
资本回报率 | -24.62% | — |
现金流
现金净变动
| (USD) | 2024年9月info | 年同比变化 |
|---|---|---|
净收入 | -1761.70万 | 61.37% |
来自运营的现金 | -5445.10万 | -20.58% |
投资现金 | -6601.80万 | -215.20% |
融资现金 | 2500.10万 | 4,094.80% |
现金净变动 | -9525.40万 | -840.01% |
自由现金流 | -4107.21万 | -62.70% |
简介
Adaptimmune is a biopharmaceutical company that develops T cell therapies against cancer. The company was founded in 2008 in the UK with links to both Oxford University and the University of Pennsylvania. It has headquarters in Philadelphia and Milton Park. In August 2024, the US Food and Drug Administration granted accelerated approval to Adaptimmune's Tecelra, a therapy against a rare form of cancer. Tecelra is the first T cell therapy to be approved for use against a solid tumor. Wikipedia
CEO
成立时间
2008
员工数量
449
